HCP Engagement in KSA: Strategies That Work in 2025

Saudi Arabia's HCP landscape has distinct characteristics that many international brands underestimate. The Kingdom has over 100,000 licensed physicians, a growing proportion of Saudi nationals entering clinical specialties through Vision 2030's medical training initiatives, and a highly consolidated hospital system where large tertiary centers — KAMC, King Faisal Specialist, Johns Hopkins Aramco Healthcare — carry enormous prescribing influence.

Relationship-driven engagement still matters, but it is no longer sufficient. HCPs report information overload from multiple company reps and are increasingly selective about the content they engage with. A 2024 survey of Saudi oncologists and diabetologists found that over 60% preferred scientific digital content over in-person rep visits as their primary channel for learning about new therapies.

SFDA's evolving regulatory stance also adds compliance complexity. While KSA does not yet have a formal Sunshine Act equivalent, SFDA's guidelines on pharmaceutical promotion — aligned with WHO and IFPMA standards — require all promotional materials to be pre-approved, all HCP interactions documented, and all educational activities to be non-promotional in substance.

1. Scientific Platform Events

Medical education events — advisory boards, symposia, investigator meetings — remain the gold standard for deep HCP engagement. The key shift is toward physician-designed agendas where KOLs drive the content, not company marketing teams. This signals genuine scientific intent and builds lasting credibility.

For specialty areas like oncology, immunology, and rare disease, national scientific societies (Saudi Oncology Society, Saudi Society of Allergy, Immunology and Clinical Immunology) are increasingly important partners. Securing an accredited CME designation through the Saudi Commission for Health Specialties (SCHS) adds significant perceived value and attendance motivation.

2. Digital and Omnichannel Touchpoints

A well-structured digital engagement layer extends the reach of in-person interactions. This includes:

• Closed-loop digital platforms where reps leave behind interactive visual aids rather than paper brochures
• Email nurturing sequences delivering peer-reviewed data, disease education content, and product updates
• On-demand CME modules accessible via mobile, allowing HCPs to engage on their own schedule
• WhatsApp-enabled medical information lines (compliant, fully documented) for rapid clinical query resolution

NPHIES integration is an emerging opportunity. As more KSA hospitals digitize clinical workflows, pharmaceutical companies that offer digital tools integrated with existing hospital systems — clinical decision support, e-detailing embedded in EMR environments — will have a structural advantage.

3. KOL Mapping and Tiered Engagement

Not all HCPs warrant the same level of investment. A well-constructed KOL map for KSA should distinguish between:

• National KOLs (academic chairs, society presidents, clinical trial PIs): engage through advisory boards, speaker programs, and global congresses
• Regional influencers (department heads, training hospital consultants): engage through local medical education and peer-to-peer events
• Emerging prescribers (residents, fellows, junior consultants): engage through society memberships, early career programs, and digital content

Tiered engagement is both more efficient and more compliant — it aligns investment with scientific influence rather than purely prescribing volume, which SFDA promotional guidelines favor.

4. Compliance as a Competitive Advantage

Companies that treat compliance as infrastructure rather than an obstacle gain trust with HCP institutions. Document every interaction. Have a formal medical affairs sign-off process for all educational materials. Establish a clear conflict-of-interest disclosure process for all speaker engagements.

Hospitals like King Faisal Specialist Hospital and Research Centre have their own vendor compliance requirements that pharma and medtech companies must satisfy before accessing HCPs. Investing in a robust SFDA-aligned compliance framework is not just risk management — it is a signal of professional seriousness that opens institutional doors.

The traditional KPI of "number of rep calls per month" is a process metric, not an outcomes metric. Advanced HCP engagement programs in KSA are shifting toward:

• Scientific share of voice at national medical conferences and in peer-reviewed publications
• HCP satisfaction scores from medical education events
• Digital engagement rates: email open rates, CME module completion, e-detail time-on-page
• Formulary and guideline inclusion: the ultimate upstream indicator of HCP conviction

Spectra Solutions MEA combines deep MENA market expertise with end-to-end event and program execution capabilities. From designing immersive booth experiences at the Saudi Health Conference to producing accredited CME symposia and building compliant digital engagement platforms, we help pharma and medtech brands build relationships with KSA's healthcare professionals that drive real clinical and commercial impact.

Ready to design an HCP engagement strategy built for the KSA market? Contact our team at service@spectra-mea.com to explore what's possible.